Safely and well invested

Values & Performance of HAEMATO AG

Have you invested in HAEMATO AG or are you interested in the company's performance as a capital market participant? Here you will find all the important information about us and our activities: Current financial reports, key figures and our financial calendar.

Directly to the share price

€ 238 mio. sales in 2020

€ 1.00 per share dividend paid in 2021

635,000 packages sold annually

31 % sales CAGR since 2007

More than 7,000 customers

Ad-Hoc Mitteilung

  • HAEMATO continues to grow strongly: in the second quarter of 2021, preliminary consolidated revenue increased by around 41% to 77.6 million euros - after already growing by 22% in the first quarter of 2021. Preliminary half-year revenue for 2021 rose to 151.5 million euros, representing year-on-year growth of 31%.
  • Preliminary EBIT rose to 4.8 million euros in the second quarter of 2021 (previous year: 0.7 million euros), corresponding to an EBIT margin of 6.2% (previous year: 1.3%).
  • Preliminary Equity increased from 125.5 million euros to 148.0 million euros as of 30 June 2021. This corresponds to an equity ratio of 78.9 %.
  • The forecast for the current business year has been increased. For the year 2021, consolidated turnover of 280 million to 300 million euros and EBIT of 9 million to 11 million euros are now expected.
  • Annual turnover in the range of 400 million euros is targeted by the end of 2023.

Rating & Research

First Berlin Equity Research

Buy: 50.00 €


Buy: 50.10 €


Zum Aktienchart
HAEMATO annual report 2020 mockup

Safely and well advised


Get an overview of the status and development of HAEMATO AG. Here you will find information about the group as well as the developments of the past years.

Read reports


We would like to inform you about the current business development of HAEMATO AG as well as about our investor relations activities.

To the news archive

Investor News

HAEMATO AG (ISIN: DE000289VV1), has continued its growth course in the first months of 2021. Due to a strong core business, consolidated sales (IFRS) increased by 22% to EUR 73.9 million in the first quarter of 2021. The specialist in drugs for the treatment of chronic diseases and for individual therapies increased earnings disproportionately at …

Ad hoc of HAEMATO AG pursuant to Art. 17 MAR: The Supervisory Board of HAEMATO AG approved the Executive Board’s proposal for the appropriation of profits at today’s balance sheet meeting. The Executive Board and Supervisory Board will therefore propose a dividend of EUR 1.00 per dividend-bearing share at the Annual General Meeting to be […]

Corporate News of HAEMATO AG: According to the preliminary IFRS financial statements for the 2020 financial year, HAEMATO AG increased its revenue by 20.5 % to EUR 238.3 million and increased EBITDA by 74.8 % to EUR 3.3 million. In the 2020 financial year, HAEMATO AG, Schoenefeld (ISIN: DE000289VV1), achieved IFRS consolidated revenues of EUR […]

Upcoming events

Preliminary Results

Q3 Results 2021

For investors

Do you have any further questions about the group? Our investor relations team is happy to help you..

Contact us